A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that excels at turning cash into shareholder value and two that may face some trouble.
Two Stocks to Sell:
ESAB (ESAB)
Trailing 12-Month Free Cash Flow Margin: 6.5%
Having played a significant role in the construction of the iconic Sydney Opera House, ESAB (NYSE: ESAB) manufactures and sells welding and cutting equipment for numerous industries.
Why Are We Hesitant About ESAB?
- Sales trends were unexciting over the last two years as its 4.2% annual growth was below the typical industrials company
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Diminishing returns on capital suggest its earlier profit pools are drying up
At $82.21 per share, ESAB trades at 13.5x forward P/E. To fully understand why you should be careful with ESAB, check out our full research report (it’s free).
Amphastar Pharmaceuticals (AMPH)
Trailing 12-Month Free Cash Flow Margin: 20.9%
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Why Does AMPH Fall Short?
- Muted 1.2% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
- Smaller revenue base of $730 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Day-to-day expenses have swelled relative to revenue over the last two years as its adjusted operating margin fell by 12.7 percentage points
Amphastar Pharmaceuticals is trading at $22.03 per share, or 6.9x forward P/E. Read our free research report to see why you should think twice about including AMPH in your portfolio.
One Stock to Buy:
IMAX (IMAX)
Trailing 12-Month Free Cash Flow Margin: 24%
Originally developed for World Expo '67 in Montreal as an innovative projection system, IMAX (NYSE: IMAX) provides proprietary large-format cinema technology and systems that deliver immersive movie experiences with enhanced image quality and sound.
What Makes IMAX Stand Out?
- Annual revenue growth of 17.9% over the last five years was superb and indicates its market share increased during this cycle
- Free cash flow margin expanded by 24.8 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Returns on capital are increasing as management’s prior bets are starting to bear fruit
IMAX’s stock price of $53.76 implies a valuation ratio of 27.3x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
